Celcuity Inc. CELC 深 滬
已收盤 10-03 16:00:00 美东时间
50.51
+1.090
+2.21%
華盛通- 最 高50.74
- 今 開49.395
- 成交量 147.62万股
- 最 低 48.585
- 昨 收 49.42
- 總市值 21.43亿
- 52周最高 63.06
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 7.575
- 委 比 -44.29%
- 總股本 4242.67万
- 歷史最高 63.06
- 量 比 1.19
- 振 幅 4.36%
- 歷史最低 4.03
- 每 手 1
- 風險率 15.23%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Needham Reiterates Buy on Celcuity, Maintains $70 Price Target
Needham analyst Gil Blum reiterates Celcuity (NASDAQ:CELC) with a Buy and maintains $70 price target.
10-03 18:38
美股大行评级 | 潜在涨幅1650.0%！Ascendiant Capital维持GRI Bio"买入"评级，目标价上调至35美元
今日重点评级关注：Ascendiant Capital：维持GRI Bio"买入"评级，目标价从34美元升至35美元；Ascendiant Capital：维持Atossa Therapeutics"买入"评级，目标价从7.5美元升至7.75美元
09-23 09:52
Guggenheim Initiates Coverage On Celcuity with Buy Rating, Announces Price Target of $110
Guggenheim analyst Brad Canino initiates coverage on Celcuity (NASDAQ:CELC) with a Buy rating and announces Price Target of $110.
09-22 18:57
Celcuity to Present Results from the Pivotal Phase 3 VIKTORIA-1 Trial at the 2025 European Society for Medical Oncology (ESMO) Congress
Celcuity Inc. announced that late-breaking clinical data from its Phase 3 VIKTORIA-1 trial will be presented at the 2025 ESMO Congress. The oral presentation will focus on the efficacy and safety of gedatolisib, a pan-PI3K and mTORC1/2 inhibitor, in HR+/HER2-/<em>PIK3CA</em> wild-type advanced breast cancer patients. Celcuity is advancing multiple clinical trials targeting solid tumors, including VIKTORIA-2 for HR+/HER2- ABC.
09-22 13:15
KAT6 Inhibitors Market Poised for Significant Growth During the Forecast Period (2025-2040) | DelveInsight
The outlook for the KAT6 inhibitors market is strengthening as interest in epig...
09-17 05:31
Celcuity Expands Credit Facility to $500 Million
The latest update is out from Celcuity ( ($CELC) ). On September 9, 2025, Celcu...
09-10 20:17
Celcuity announces upsized loan facility of $500M
Celcuity (NASDAQ:CELC) said on Tuesday that it has entered into an amendment to its existing senior secured credit facility with an affiliate of Innovatus Capital Partners and Oxford Finance and its a...
09-10 04:19
Abivax’s 580% surge hands biotech hedge funds a rare 2025 win
Hedge funds specializing in biotech finally caught a break this summer, courtesy of a little-watched French drug developer, The Wall Street Journal reported on Saturday. Paris-based Abivax (NASDAQ:ABV...
08-31 20:30
Celcuity's NDA For Gedatolisib In HR+/HER2- Breast Cancer Accepted Into FDA's Real-Time Oncology Review Program
Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced the U.S. Food and Drug Administration ("FDA") agreed to accept its New Drug
08-28 04:14
Celcuity to Initiate NDA Submission of Gedatolisib in PIK3CA Wild-Type Cohort in HR+/HER2- Advanced Breast Cancer Under FDA’s Real-Time Oncology Review Program
Celcuity宣布FDA接受其针对HR+/HER2-晚期乳腺癌的药物gedatolisib的新药申请(NDA)并拟采用RTOR计划以加速审查。基于III期VIKTORIA-1试验中PIK3CA野生型队列的积极数据， Gedatolisib三联和双联疗法均显示出显著降低疾病进展或死亡风险，并在中位无进展生存期(PFS)上相比单独使用氟维司群有显著改善。
08-27 20:05
